The present invention provides multifunctional monomers, including, but not limited to include multifunctional methylene malonate and methylene beta-ketoester monomers; methods for producing the same; and compositions and products formed therefrom. The multifunctional monomers of the invention may be produced by transesterification or by direct synthesis from monofunctional methylene malonate monomers or methylene beta-ketoester monomers. The present invention further compositions and products formed from methylene beta-ketoester monomers of the invention, including monomer-based products (e.g., inks, adhesives, coatings, sealants or reactive molding) and polymer-based products (e.g., fibers, films, sheets, medical polymers, composite polymers and surfactants).

Disclosed are methods for the catalytic transesterification of compounds having one or more ester groups and groups reactive under transesterification conditions, such as 1,1-disubstituted alkene compounds, with alcohols or esters and novel compositions prepared therefrom. Further disclosed are novel compounds and compositions prepared as a result of the methods.

Disclosed are methods for the catalytic transesterification of compounds having one or more ester groups and groups reactive under transesterification conditions, such as 1,1-disubstituted alkene compounds, with alcohols or esters and novel compositions prepared therefrom. Further disclosed are novel compounds and compositions prepared as a result of the methods.

Disclosed are methods for the catalytic transesterification of compounds having one or more ester groups and groups reactive under transesterification conditions, such as 1,1-disubstituted alkene compounds, with alcohols or esters and novel compositions prepared therefrom. Further disclosed are novel compounds and compositions prepared as a result of the methods.

Provided herein are reactor systems and processes for producing organic acids directly from beta-lactones. Such reactor systems and processes involve the use of a heterogeneous catalyst, such as a zeolite at vapor phase conditions. The reactor systems and processes may use a fixed bed, moving bed or fluidized contacting zone as reactor configurations.

Provided herein are reactor systems and processes for producing organic acids directly from beta-lactones. Such reactor systems and processes involve the use of a heterogeneous catalyst, such as a zeolite at vapor phase conditions. The reactor systems and processes may use a fixed bed, moving bed or fluidized contacting zone as reactor configurations.

Provided is a compound represented by Formula (1) given below. (In the formula, R.sup.1 represents a hydrogen atom or a methyl group, R.sup.2 represents a hydrogen atom, a phenyl group, a C.sub.1 to 8 alkyl group, or a C.sub.1 to 4 perfluoroalkyl group, X.sup.1 represents a hydrogen atom or a hydroxy group, Y.sup.1 represents a C.sub.1 to 9 alkylene group containing a fluorine atom or a C.sub.1 to 9 alkylene group containing no fluorine atom, and n.sup.1 is an integer from 0 to 3.).

A lubricity modifier for fuels contain a dicarboxylic acid monoester compound represented by formula (I). In formula (I), R.sub.1 represents a single bond, a substituted or unsubstituted C.sub.2-6 divalent alkenyl group, or a group having a structure of R.sub.3R.sub.4R.sub.5; R.sub.2 represents a substituted or unsubstituted C.sub.1-40 hydrocarbyl group; R.sub.3 and R.sub.5 each independently represents a single bond, or a substituted or unsubstituted C.sub.1-3 divalent alkyl group; and R.sub.4 represents a substituted or unsubstituted C.sub.3-12 divalent alicyclic group. ##STR00001##

A lubricity modifier for fuels contain a dicarboxylic acid monoester compound represented by formula (I). In formula (I), R.sub.1 represents a single bond, a substituted or unsubstituted C.sub.2-6 divalent alkenyl group, or a group having a structure of R.sub.3R.sub.4R.sub.5; R.sub.2 represents a substituted or unsubstituted C.sub.1-40 hydrocarbyl group; R.sub.3 and R.sub.5 each independently represents a single bond, or a substituted or unsubstituted C.sub.1-3 divalent alkyl group; and R.sub.4 represents a substituted or unsubstituted C.sub.3-12 divalent alicyclic group. ##STR00001##

Citraconic acid (CA) or derivative thereof for use as medicament, for example in the treatment of a medical condition associated with inflammation. In another aspect, the invention relates to a citraconic acid derivative according to formulae 1-XIII. In another aspect, the invention relates to a pharmaceutical composition comprising citraconic acid or derivative thereof with one or more pharmaceutical excipients for use in the treatment of a medical condition, such as those associated with inflammation and/or a non-inflammation associated medical condition.